NO20024321D0 - Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin - Google Patents

Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin

Info

Publication number
NO20024321D0
NO20024321D0 NO20024321A NO20024321A NO20024321D0 NO 20024321 D0 NO20024321 D0 NO 20024321D0 NO 20024321 A NO20024321 A NO 20024321A NO 20024321 A NO20024321 A NO 20024321A NO 20024321 D0 NO20024321 D0 NO 20024321D0
Authority
NO
Norway
Prior art keywords
cabergoline
preparation
crystalline form
crystalline
Prior art date
Application number
NO20024321A
Other languages
English (en)
Other versions
NO20024321L (no
Inventor
Attilio Tomasi
Stefania Magenes
Mario Ungari
Giuliano Ramella
Giafranco Pallanza
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024321(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20024321L publication Critical patent/NO20024321L/no
Publication of NO20024321D0 publication Critical patent/NO20024321D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
NO20024321A 2000-03-24 2002-09-10 Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin NO20024321D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
NO20024321L NO20024321L (no) 2002-09-10
NO20024321D0 true NO20024321D0 (no) 2002-09-10

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024321A NO20024321D0 (no) 2000-03-24 2002-09-10 Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin

Country Status (31)

Country Link
US (2) US6727363B2 (no)
EP (1) EP1272489B1 (no)
JP (1) JP4184666B2 (no)
KR (1) KR100827558B1 (no)
CN (1) CN1188412C (no)
AR (1) AR032449A1 (no)
AT (1) ATE250601T1 (no)
AU (2) AU780747B2 (no)
BR (1) BR0109507A (no)
CA (1) CA2402836A1 (no)
CZ (1) CZ20023176A3 (no)
DE (1) DE60100858T2 (no)
DK (1) DK1272489T3 (no)
EA (1) EA005928B1 (no)
EE (1) EE05088B1 (no)
ES (1) ES2208602T3 (no)
GB (1) GB0007308D0 (no)
HK (1) HK1052348B (no)
HU (1) HUP0300591A3 (no)
IL (2) IL150985A0 (no)
MX (1) MXPA02009283A (no)
MY (1) MY134189A (no)
NO (1) NO20024321D0 (no)
NZ (1) NZ521316A (no)
PE (1) PE20011140A1 (no)
PL (1) PL358253A1 (no)
PT (1) PT1272489E (no)
SI (1) SI1272489T1 (no)
SK (1) SK13582002A3 (no)
WO (1) WO2001070740A1 (no)
ZA (1) ZA200206045B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
EP1485383A1 (en) * 2002-03-15 2004-12-15 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
KR100605794B1 (ko) * 2002-03-15 2006-08-01 파마시아 코포레이션 카베르골린의 제1형 결정을 제조하는 방법
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
CA2525104A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
EP0664705B1 (en) 1993-08-18 2000-10-04 Alcon Laboratories, Inc. Compositions of ergoline derivatives for the treatment of glaucoma
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
US6114326A (en) 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline

Also Published As

Publication number Publication date
PE20011140A1 (es) 2001-11-01
PL358253A1 (en) 2004-08-09
EA200201016A1 (ru) 2003-02-27
HUP0300591A2 (hu) 2003-07-28
EP1272489B1 (en) 2003-09-24
JP4184666B2 (ja) 2008-11-19
MXPA02009283A (es) 2003-03-12
AR032449A1 (es) 2003-11-12
NO20024321L (no) 2002-09-10
HK1052348B (zh) 2005-09-16
CN1419554A (zh) 2003-05-21
ZA200206045B (en) 2003-07-29
GB0007308D0 (en) 2000-05-17
IL150985A (en) 2007-03-08
US20030149067A1 (en) 2003-08-07
AU2005203071A1 (en) 2005-08-11
HK1052348A1 (en) 2003-09-11
CN1188412C (zh) 2005-02-09
EA005928B1 (ru) 2005-08-25
AU780747B2 (en) 2005-04-14
DE60100858T2 (de) 2004-07-29
KR100827558B1 (ko) 2008-05-07
MY134189A (en) 2007-11-30
EP1272489A1 (en) 2003-01-08
NZ521316A (en) 2004-05-28
AU2005203071B2 (en) 2007-10-18
IL150985A0 (en) 2003-02-12
EE05088B1 (et) 2008-10-15
ATE250601T1 (de) 2003-10-15
DE60100858D1 (de) 2003-10-30
ES2208602T3 (es) 2004-06-16
CZ20023176A3 (cs) 2003-02-12
JP2003528100A (ja) 2003-09-24
KR20020081587A (ko) 2002-10-28
HUP0300591A3 (en) 2009-01-28
EE200200545A (et) 2004-04-15
US6727363B2 (en) 2004-04-27
SI1272489T1 (en) 2004-02-29
US6953854B2 (en) 2005-10-11
SK13582002A3 (sk) 2003-04-01
PT1272489E (pt) 2004-02-27
AU6211001A (en) 2001-10-03
WO2001070740A1 (en) 2001-09-27
US20040092744A1 (en) 2004-05-13
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
DK1272489T3 (da) 2003-12-15

Similar Documents

Publication Publication Date Title
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20013943D0 (no) Fremgangsmate for fremstilling av Citalopram
NO20024321D0 (no) Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin
NO20030163L (no) Fremgangsmate for fremstilling av olefiner
NO20032731D0 (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
NO20024527D0 (no) Krystallinsk form II av kabergolin
NO20025423L (no) Fremgangsmate for fremstilling av Citalopram
NO20026155D0 (no) Fremgangsmåte for fremstilling av lavere olefiner
NO20021118D0 (no) Fremgangsmåte for fremstilling av citalopram
HUP0101875A3 (en) Process for the preparation of piperidine derivatives
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
NO20000965D0 (no) Fremgangsmåte for fremstilling av veksthormon-utskillende forbindelser
EP1176150A4 (en) A METHOD FOR PRODUCING TRIFLUOROTHYMIDINE DERIVATIVES
NO20024887D0 (no) Fremgangsmåte for fremstilling av benzokondenserte heterosykliske forbindelser
NO20023702L (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20032297L (no) Fremgangsmåte for fremstilling av distamycinderivater
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20025385L (no) Fremgangsmate for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20013044L (no) Fremgangsmåte for fremstilling av NG-substituerte deaza- adenosinderivater
NO20012811D0 (no) Fremgangsmåte for fremstilling av p-klorfenyl-propanol- derivat
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20022671D0 (no) Fremgangsmåte for fremstilling av tienopyrimidiner
NO20013453D0 (no) Fremgangsmåte for fremstilling av salter av cyanobenzylaminer
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application